Gene therapy shot aims to cut eye injections for diabetic vision loss
NCT ID NCT05930561
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tests a gene therapy called 4D-150 for diabetic macular edema, a condition that causes vision loss in people with diabetes. The study involves 72 adults who will receive either the gene therapy or standard aflibercept injections. The goal is to see if a single dose of gene therapy can reduce the need for frequent eye injections over two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
4D-150 gene therapy
What this could lead to
If successful, this gene therapy could reduce the number of eye injections needed to control diabetic macular edema, potentially improving quality of life.
What could go wrong
This is an early phase 2 trial with only 72 participants. The therapy may not work as hoped, and there are risks from the injection and gene therapy itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Clinical Research
Austin, Texas, 78750, United States
-
Cumberland Valley Retina Consultants
Hagerstown, Maryland, 21740, United States
-
Emanuelli Research and Development Center
Arecibo, X00612, Puerto Rico
-
Erie Retina Research
Erie, Pennsylvania, 16507, United States
-
Piedmont Eye Center
Lynchburg, Virginia, 24502, United States
-
Verum Research, LLC
Eugene, Oregon, 97401, United States